Journal
NEURO-ONCOLOGY
Volume 12, Issue 1, Pages 14-18Publisher
DUKE UNIV PRESS
DOI: 10.1093/neuonc/nop010
Keywords
bevacizumab; neurofibromatosis type 2; vestibular schwannoma
Categories
Ask authors/readers for more resources
Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available